Screener
Spyre Therapeutics, Inc. SYRE EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Spyre Therapeutics, Inc.’s reported figures.
Based on trailing twelve months.
The source filing: Spyre Therapeutics, Inc.’s 10-Q, filed August 7, 2024. Open the filing →
- Filed
- Aug 7, 2024
- Fiscal quarter
- Q2 FY2024
- Calendar quarter
- Q2 2024
- Accession
- 0001636282-24-000051
FAQ
- What is Spyre Therapeutics, Inc.'s EBITDA margin?
- Spyre Therapeutics, Inc. (SYRE) reported EBITDA margin of -17,462.5% in Q2 2023.
- How has Spyre Therapeutics, Inc.'s EBITDA margin changed year-over-year?
- Spyre Therapeutics, Inc.'s EBITDA margin decreased by 1327.5% year-over-year, from -1,223.3% to -17,462.5%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about Spyre Therapeutics, Inc.'s ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude